

Aurora Cannabis Inc

Fact Sheet

A C B

LISTED

NASDAQ

Toronto Stock Exchange: ACB

ARUORA CANNABIS

QUICK REFERENCE

Aurora Cannabis Inc.

Nasdaq: **ACB**

www.AURORAMJ.com

BUSINESS SUMMARY

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

SCIENCE & INNOVATION

New Products

We're shaping a bright future for the industry through better plants.

- Grown with traditional breeding methods in use for over a century
- Crop innovation techniques in line with those used for corn, wheat, and other major global agricultural crops
- Focused on improving potency, terpenes, flowers, plant architecture, maturity, and yield

Genetics Licensing

We have Canada's largest catalogue of high-quality cannabis genetics.

- Over 20 exclusive cultivars immediately available for trial and licensing
- New cultivars consistently test high for THC, with some growers testing above 30%
- Measured yields as high as 600-900 g/m² (2-3 oz/sf), with numbers continuing to grow each year

Research & Development

Aurora Coast, our state-of-the-art facility in Comox Valley, British Columbia is one of the world's most advanced.

- Over 18,000 square feet of dedicated greenhouse space
- Nearly 10,000 unique genotypes grown and tested annually to select ideal traits
- Active support of medical research at every stage of the drug development pathway
- An unmatched team of experts in genomics, biotechnology, analytics & testing, tissue culture, biomedical research, and product innovation

Optimization

Our science-backed approach lets us unlock the true commercial potential of cannabis.

- Aroma and sensory profiles selected for maximum consumer appeal
- Improved maturity and sustainability
- Resistance to mildew and other fungal pathogens

CONTACT INFORMATION

Headquarters
3498 63 Avenue
Leduc, Alberta, Canada

Barwicki Investor Relations
Andrew Barwicki
516-662-9461 / andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

Aurora Completes Final Repayment of Convertible Senior Notes Representing \$465 Million in Total Repayments Since 2021; Cannabis Operations Are Now Debt Free

Feb. 29, 2024 - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced that it has repaid an aggregate of approximately \$7.2 million (US\$5.3 million), representing the final payment on the principal amount of its convertible senior notes ("Notes") at a total cash cost of \$7.4 million (~US\$5.5 million), including accrued interest. Following the completion of this repayment, Aurora's remaining debt of \$47.9 million relates to Bevo Farms Ltd.

Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis

- ***Partnership will empower UK patients with valuable information and guidance critical to a successful cannabis experience***

Feb. 28, 2024 - Aurora Cannabis Inc. announced the partnership of Aurora Medicine UK Ltd with Script Assist, a cutting-edge medical cannabis prescription platform in the UK.

Designed to support UK patients on their journey of well-being, the Script Assist platform provides access to high quality medication through their portal. Script Assist will make available an extensive range of medical cannabis products from Aurora's leading portfolio of products. Starting in March three newly launched, high-quality hand-dried and hand-processed flower products from Aurora's EU GMP facilities in Canada will also become available on www.scriptassist.co.uk: Pedanios 26/1 EHD-CA (Cultivar: Electric Honey Dew) and Pedanios 28/1 CMK-CA (Cultivar: Chemango Kush) with a high THC content, as well as Pedanios 10/10 EQI-CA (Cultivar: Equiposa) with balanced THC/CBD content.

Within the platform, Script Assist is launching 'Find a Doctor', an easy-to-use app, which seamlessly connects patients with specialist prescribing doctors. The full range of Aurora's medical cannabis products will be available for patients through prescription by all private doctors and clinics using the platform, transforming the UK medical cannabis prescription journey.

Aurora Cannabis Announces Fiscal 2024 Third Quarter Results; Generates Record Adjusted EBITDA of \$4.3 Million

- ***Re-Affirms Commitment to Achieving Positive Free Cash Flow¹ This Calendar Year, Delivers Fifth Consecutive Quarter of Positive Adjusted EBITDA¹***
- ***Aurora Becomes the Largest Global Medical Cannabis Company in Nationally Legal Markets Following the Acquisition of MedReleaf Australia***
- ***Strong YoY Growth of 41% in High Margin International Net Cannabis Revenue***
- ***Cash position of over \$200 Million as of Quarter Close, Remaining Convertible Debt of \$7.3 Million to be Fully Repaid in February***

Feb. 8, 2024 - Aurora Cannabis Inc. announced its financial and operational results for the third quarter of fiscal year 2024. As the fiscal year 2023 consisted of three quarters, the year-over-year comparison quarter for Q3 2024 ending December 31, 2023, is Q2 2023 ending December 31, 2022.

Third Quarter 2024 Highlights

(Unless otherwise stated, comparisons are made between fiscal Q3 2024, Q2 2024, and Q2 2023 results and are in Canadian dollars)

Consolidated Revenue and Adjusted Gross Profit:

Total net revenue was \$64.4 million, as compared to \$61.1 million in the prior year period. The increase from the prior period is mainly due to growth in our global medical cannabis business and higher quarterly revenue in our plant propagation business, partially offset by a decline in our consumer cannabis net revenue.

Consolidated adjusted gross margin before fair value adjustments¹ was 50% in Q3 2024 compared 46% in the prior year quarter. Adjusted gross profit before FV adjustments¹ was \$32.4 million in Q3 2024 (vs \$28.0 prior year quarter, an increase of 15.7%).

This Company Fact Sheet is distributed by Andrew Barwicki, Investor Relations. Contact Info: 516-662-9461 / andrew@barwicki.com
The information contained is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned. This Company Fact Sheet is an information publication and is considered investor relations & financial public relations material. All information is compiled from SEC Filings (U.S. Securities and Exchange Commission), press releases, conference calls, shareholder meetings, investment conferences, analyst reports, internet, company website and/or senior management interviews. This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Aurora Cannabis Inc.

NASDAQ: ACB

TSX: ACB

www.auroramj.com

Barwicki Investor Relations • 30 Wall Street, 8 FL, New York, NY 10005

Deliver to: